Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy

被引:23
作者
Lee, Hyun-Jung [1 ]
Kim, Hyung-Kwan [1 ]
Kim, Bong-Sung [2 ]
Han, Kyung-Do [2 ]
Park, Jun-Bean [1 ]
Lee, Heesun [1 ]
Lee, Seung-Pyo [1 ]
Kim, Yong-Jin [1 ]
机构
[1] Seoul Natl Univ Hosp, Cardiovasc Ctr, Dept Internal Med, Div Cardiol, Seoul, South Korea
[2] Soongsil Univ, Dept Stat & Actuarial Sci, Seoul, South Korea
关键词
NONVALVULAR ATRIAL-FIBRILLATION; DABIGATRAN ETEXILATE; SAFETY; PHARMACOKINETICS; WARFARIN; PHARMACODYNAMICS; PREVENTION; APIXABAN; STROKE; TRACT;
D O I
10.1371/journal.pone.0253310
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Proton pump inhibitors (PPIs) are known to reduce the risk of upper gastrointestinal bleeding in patients on oral anticoagulants, and patients are increasingly on oral anticoagulants and PPI co-therapy. However, evidence is lacking on the safety and effectiveness of oral anticoagulants when co-administered with PPIs. Methods Among patients initiating oral anticoagulants (warfarin and non-vitamin K antagonist oral anticoagulants [NOACs], i.e. rivaroxaban, dabigatran, apixaban, and edoxaban) during 2013-2017, those concomitantly prescribed PPIs were identified (n = 19,851). The primary endpoint was hospitalization for major upper gastrointestinal bleeding, and secondary endpoints were death and ischemic stroke. Results During a mean 1.4 years of follow-up, the primary endpoint occurred in 512 (2.58%) patients. Overall, NOACs were associated with lower upper gastrointestinal bleeding risk after adjustment for age, sex, comorbidities and concomitant medications (adjusted hazard ratio 0.78, 95% confidence interval 0.65-0.94), compared to warfarin. There was no significant difference in upper gastrointestinal bleeding risk among the individual NOACs. This trend of reduced risk for upper gastrointestinal bleeding in NOACs compared to warfarin was consistent for both regular and reduced doses, throughout bleeding risk groups, and other subgroup analyses. NOACs were also associated with lower risk of death compared to warfarin. The risk for ischemic stroke was not significantly different among the oral anticoagulants in patients with atrial fibrillation. Conclusion In patients on oral anticoagulant and PPI co-therapy, NOACs were associated with lower risk of upper gastrointestinal bleeding and mortality compared to warfarin, while there was no difference among the oral anticoagulants for stroke prevention. In patients on PPI therapy, NOACs may preferred over warfarin for decreasing risk of upper gastrointestinal bleeding and mortality.
引用
收藏
页数:15
相关论文
共 36 条
[1]   Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study [J].
Abraham, Neena S. ;
Noseworthy, Peter A. ;
Yao, Xiaoxi ;
Sangaralingham, Lindsey R. ;
Shah, Nilay D. .
GASTROENTEROLOGY, 2017, 152 (05) :1014-+
[2]   Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy [J].
Agewall, Stefan ;
Cattaneo, M. ;
Collet, J. P. ;
Andreotti, F. ;
Lip, G. Y. H. ;
Verheugt, F. W. A. ;
Huber, K. ;
Grove, E. L. ;
Morais, J. ;
Husted, S. ;
Wassmann, S. ;
Rosano, G. ;
Atar, D. ;
Pathak, A. ;
Kjeldsen, K. ;
Storey, R. F. .
EUROPEAN HEART JOURNAL, 2013, 34 (23) :1708-+
[3]  
Aronow Wilbert S, 2009, J Atr Fibrillation, V1, P154, DOI 10.4022/jafib.154
[4]   ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents [J].
Bhatt, Deepak L. ;
Scheiman, James ;
Abraham, Neena S. ;
Antman, Elliott M. ;
Chan, Francis K. L. ;
Furberg, Curt D. ;
Johnson, David A. ;
Mahaffey, Kenneth W. ;
Quigley, Eamonn M. ;
Harrington, Robert A. ;
Bates, Eric R. ;
Bridges, Charles R. ;
Eisenberg, Mark J. ;
Ferrari, Victor A. ;
Hlatky, Mark A. ;
Kaul, Sanjay ;
Lindner, Jonathan R. ;
Moliterno, David J. ;
Mukherjee, Debabrata ;
Schofield, Richard S. ;
Rosenson, Robert S. ;
Stein, James H. ;
Weitz, Howard H. ;
Wesley, Deborah J. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (18) :1502-1517
[5]   Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study [J].
Chan, Esther W. ;
Lau, Wallis C. Y. ;
Leung, Wai K. ;
Mok, Michael T. C. ;
He, Ying ;
Tong, Teresa S. M. ;
Wong, Ian C. K. .
GASTROENTEROLOGY, 2015, 149 (03) :586-+
[6]   Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Yusuf, Salim ;
Eikelboom, John ;
Oldgren, Jonas ;
Parekh, Amit ;
Pogue, Janice ;
Reilly, Paul A. ;
Themeles, Ellison ;
Varrone, Jeanne ;
Wang, Susan ;
Alings, Marco ;
Xavier, Denis ;
Zhu, Jun ;
Diaz, Rafael ;
Lewis, Basil S. ;
Darius, Harald ;
Diener, Hans-Christoph ;
Joyner, Campbell D. ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151
[7]   Novel oral anticoagulant drugs and severe oesophagitis dissecans [J].
Cox, R. ;
Roche, E. ;
Fairley, S. .
INTERNAL MEDICINE JOURNAL, 2016, 46 (12) :1456-1457
[8]   Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs) [J].
Gelosa, Paolo ;
Castiglioni, Laura ;
Tenconi, Marco ;
Baldessin, Ludovico ;
Racagni, Giorgio ;
Corsini, Alberto ;
Bellosta, Stefano .
PHARMACOLOGICAL RESEARCH, 2018, 135 :60-79
[9]   Aging, the gastrointestinal tract, and risk of acid-related disease [J].
Greenwald, DA .
AMERICAN JOURNAL OF MEDICINE, 2004, 117 :8S-13S
[10]   The potential drug-drug interaction between proton pump inhibitors and warfarin [J].
Henriksen, Daniel Pilsgaard ;
Stage, Tore Bjerregaard ;
Hansen, Morten Rix ;
Rasmussen, Lotte ;
Damkier, Per ;
Pottegard, Anton .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 (12) :1337-1340